Two Decades of FAERS Data Reveal Known Risks and Rare Late-Onset Adverse Effects of Venlafaxine

An analysis of two decades of data from the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) has provided insights into the safety profile of venlafaxine, a commonly prescribed antidepressant. The findings highlight both established risks associated with the medication and rare late-onset adverse events, as well as patterns observed in specific patient subgroups. Researchers examined long-term prescribing implications based on these real-world reports.

The study utilized FAERS data to identify trends and occurrences related to venlafaxine use over 20 years. Known risks linked to the drug were confirmed, while rare adverse effects that appeared later in treatment were also documented. Additionally, subgroup analyses revealed distinct patterns among certain populations, offering further understanding of how different demographics may experience side effects differently. These findings aim to inform healthcare professionals about potential considerations for long-term prescribing practices.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: February 11, 2026

Author

GOAI